Objective:
To explore new therapeutic agents aimed at reducing treatment burden and preserving vision in patients with neovascular age-related macular degeneration (nAMD), highlighting the significance of these advancements.
Key Findings:
- EYP-1901 showed noninferiority to aflibercept with reduced treatment burden in phase 2 trials (DAVIO 2).
- OTX-TKI demonstrated significant treatment burden reduction with comparable visual acuity in early trials (SOL-1, SOL-R).
- Various TKIs are in development with innovative delivery methods, including topical and subcutaneous formulations.
Interpretation:
The advancements in TKIs and their delivery methods may lead to more effective and less burdensome treatments for nAMD, potentially improving patient outcomes and quality of life.
Limitations:
- Current studies are primarily in early to mid-phase trials, and long-term efficacy and safety data are still needed, with potential biases in trial designs.
- Variability in patient responses and the need for rescue injections complicate treatment assessments.
Conclusion:
Emerging therapies for nAMD, particularly TKIs, show promise in reducing treatment burden and improving vision outcomes, warranting further investigation in ongoing clinical trials to validate these findings.
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.